Latest News of SPRY
ARS Pharmaceuticals (SPRY): A Bull Case Theory
By Yahoo! Finance |
3 weeks ago
ARS Pharmaceuticals presents a strong investment opportunity with its FDA-approved needle-free epinephrine nasal spray, Neffy, aiming to disrupt the EpiPen market. With potential for significant marke...
ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares
By Yahoo! Finance |
1 month ago
On August 20, 2024, Kathleen Scott, CFO of ARS Pharmaceuticals Inc, sold 12,500 shares at $16/share. The company focuses on developing health solutions. With a market cap of $1.299 billion, investors ...
Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY)
By Yahoo! Finance |
1 month ago
Brian Dorsey, COO of ARS Pharmaceuticals Inc (NASDAQ:SPRY), sold 30,000 shares, now owning 6,024 shares. The company focuses on developing innovative drug products, primarily epinephrine for severe al...
-
Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),
By Yahoo! Finance | 3 months agoIn ARS Pharmaceuticals, institutional investors hold a 30% stake, making them the most powerful shareholder group. Hedge funds, insiders, and private equity firms also have significant ownership. Anal...